Information Provided By:
Fly News Breaks for November 14, 2019
Nov 14, 2019 | 16:34 EDT
Stifel analyst Daniel Arias initiated coverage of Repligen with a Buy rating and $105 price target. As a bioproduction pure play, Repligen "sits squarely within the sweet spot" of the collective life sciences customer base, Arias tells investors in a research note. He believes the portfolio is well positioned and new products are set to launch that can drive incremental 2020 and 2021 growth.
News For RGEN From the Last 2 Days
There are no results for your query RGEN